Loxicom (5 mg/mL meloxicam) Injection, by Norbrook, is an FDA-approved injectable non-steroidal anti-inflammatory (NSAID) medication for use in dogs and cats. Controls post-operative pain/inflammation in cats associated with orthopedic surgery, ovariohysterectomy and castration when administered prior to surgery, and pain/inflammation associated with OA in dogs for up to 24 hours.
Each ml contains:
Meloxicam 5 mg/ml
Ethanol, anhydrous 150mg/ml
UsesDogs: Alleviation of inflammation and pain in both
acute and chronic musculo-skeletal disorders. Reduction of postoperative
pain and inflammation following orthopaedic and soft tissue surgery.
Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Dosage & AdministrationDogs:
Single administration of 0.2mg Meloxicam/kg bodyweight (i.e. 0.4ml/10kg).
Musculo-skeletal disorders: Single subcutaneous injection.
Loxicom 1.5 mg/ml oral suspension may be used for continuation of
treatment at a dosage of 0.1 mg Meloxicam/kg bodyweight, 24 hours after
administration of the injection.
Reduction of post-operative pain (over a period of 24 hours):
Single intravenous or subcutaneous injection before surgery, for example at the time of induction of anaesthesia.
Single administration of 0.3mg Meloxicam/kg bodyweight (i.e. 0.06ml/kg).
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: Single subcutaneous injection before surgery, for example at the time of induction of anaesthesia.
Particular care should be taken with regard to the accuracy of dosing.
Avoid introduction of contamination during use.
Contraindictions, Warnings etcDo not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as
irritation and haemorrhage, impaired hepatic, cardiac or renal function
and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less than 2kg.
Typical adverse reactions of non-steroidal anti-inflammatory drugs
NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult
blood, apathy and renal failure have occasionally been reported. In
dogs, these adverse reactions occur generally within the first treatment
week and are in most cases transient and disappear following
termination of the treatment but in very rare cases may be serious or
fatal. In very rare cases anaphylactoid reactions may occur and
should be treated symptomatically.
If you notice any serious effects or other effects not mentioned in this
leaflet, please inform your veterinary surgeon. For post-operative pain
relief in cats, safety has only been documented after
If adverse effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Do not use an oral follow-up therapy containing meloxicam or other
NSAIDs in cats, as no safe dosage for repeated oral administration has
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and
substances with high protein binding may compete for binding and thus
lead to toxic effects. Loxicom must not be administered in conjunction
with other NSAIDs or glucocorticosteroids. Concurrent administration of
potential nephrotoxic drugs should be avoided. In animals at anaesthetic
risk (e.g. aged animals) intravenous or subcutaneous fluid therapy
during anaesthesia should be taken into consideration. When anaesthesia
and NSAID are concomitantly administered, a risk for renal function
cannot be excluded.
Pre-treatment with anti-inflammatory substances may result in additional
or increased adverse effects and accordingly a treatment-free period
with such drugs should be observed for at least 24 hours before
commencement of treatment. The treatment-free period, however, should
take into account the pharmacokinetic properties of the products used
previously. In the case of overdose symptomatic treatment should be
Operator warnings: Accidental self-injection may give
rise to pain. People with known hypersensitivity to NSAIDs should avoid
contact with the veterinary medicinal product. In case of accidental
self-injection, seek medical advice immediately and show this package
leaflet or the label to the physician.
Pharmaceutical PrecautionsThis veterinary medicinal product does not require any special storage conditions.
Shelf-life after first opening the container 28 days.
Do not use after the expiry date stated on the carton and the bottle.
Dispose of any unused product and empty container in accordance with guidance from your local waste regulation authority.
Further InformationMeloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the
oxicam class which acts by inhibition of prostaglandin synthesis,
thereby exerting anti-inflammatory, analgesic, antiexudative and
antipyretic effects. It reduces leukocyte infiltration into the inflamed
tissue. To a minor extent it also inhibits collagen-induced thrombocyte
aggregation. In vitro and in vivo studies demonstrated that meloxicam
inhibits cyclooxygenase 2 (COX 2) to a greater extent than
cyclooxygenase 1 (COX 1).
Following subcutaneous administration, meloxicam is completely
bioavailable and maximal mean plasma concentrations of 0.73?g/ml in dogs
and 1.1 ?g/ml in cats were reached approximately 2.5 hours and 1.5
hours postadministration, respectively.
There is a linear relationship between the dose administered and plasma
concentration observed in the therapeutic dose range in dogs. More than
97% of meloxicam is bound to plasma proteins. The volume of distribution
is 0.3 l/kg in dogs and 0.09 l/kg in cats. In dogs, meloxicam is
predominantly found in plasma and is also a major biliary excretion
product whereas urine contains only traces of the parent compound.
Meloxicam is metabolised to an alcohol, an acid derivative
and to several polar metabolites. All major metabolites have been shown
to be pharmacologically inactive. Meloxicam is eliminated with a
half-life of 24 hours in dogs and 15 hours in cats. Approximately 75% of
the administered dose is eliminated via faeces and the remainder via